Cardiovascular Research Group, Manchester Academic Health Sciences Centre, University of Manchester, Manchester, UK.
Lancet. 2010 Aug 14;376(9740):540-50. doi: 10.1016/S0140-6736(10)60445-X. Epub 2010 Jul 15.
Much evidence shows that the marine omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid have beneficial effects in various cardiac disorders, and their use is recommended in guidelines for management of patients after myocardial infarction. However, questions have been raised about their usefulness alongside optimum medical therapies with agents proven to reduce risk of cardiac events in high-risk patients. Additionally, there is some evidence for a possible pro-arrhythmic effect in subsets of cardiac patients. Some uncertainly exists about the optimum dose needed to obtain beneficial effects and the relative merit of dietary intake of omega-3 polyunsaturated fatty acids versus supplements. We review evidence for the effects of omega-3 polyunsaturated fatty acids on various cardiac disorders and the risk factors for cardiac disease. We also assess areas of uncertainty needing further research.
大量证据表明,海洋 ω-3 脂肪酸二十碳五烯酸和二十二碳六烯酸对各种心脏疾病具有有益作用,其使用在心肌梗死后患者管理指南中得到推荐。然而,对于在已证实可降低高危患者心脏事件风险的药物的最佳药物治疗基础上联合使用这些物质的有效性,人们提出了疑问。此外,在某些亚组心脏患者中,这些物质可能具有致心律失常作用。对于获得有益效果所需的最佳剂量以及 ω-3 多不饱和脂肪酸的饮食摄入与补充剂之间的相对优点,仍存在一些不确定性。我们综述了 ω-3 多不饱和脂肪酸对各种心脏疾病和心脏疾病危险因素的影响,并评估了需要进一步研究的不确定领域。